Houston-based biomaterials company raises $1.1M to grow team, build new HQ

money moves

BUCHA BIO has raised over $1 million to grow its team, build a new headquarters, and accelerate its go-to-market strategy. Image courtesy of BUCHA BIO

A Houston company that has created a plant-based material that can replace unsustainable conventional leathers and plastics has announced the close of its oversubscribed seed funding round.

BUCHA BIO announced it's raised $1.1 million in seed funding. The round included participation from existing partners New Climate Ventures, Lifely VC, and Beni VC, as well as from new partners Prithvi VC, Asymmetry VC, and investors from the Glasswall Syndicate, including Alwyn Capital, as well as Chris Zarou, CEO & Founder of Visionary Music Group and manager of multi-platinum Grammy-nominated rapper, Logic, the startup reports in a news release.

“I’m excited to back BUCHA BIO’s amazing early market traction," Zarou says in the release. "Their next-gen bio-based materials are game-changing, and their goals align with my personal vision for a more sustainable future within the entertainment industry and beyond.”

The company, which relocated its headquarters from New York to Houston in February, was founded by Zimri T. Hinshaw in 2020 and is based out of the East End Makers Hub and Greentown Houston.

BUCHA BIO has created two bio-based materials using bacterial nanocellulose and other plant-based components. The two materials are SHORAI, which can be used as a leather alternative, and HIKARI, a translucent material that is expected to be formally introduced in November.

The fresh funding will help the company to accelerate its move into the marketplace next year by securing co-manufacturers to scale production. Additionally, the company is growing its team and is hiring for a new supply chain lead as well as some technician roles.

Per the release, BUCHA BIO is working on constructing a new headquarters in Houston that will house a materials development laboratory, prototype manufacturing line, and offices.

BUCHA BIO has the potential to impact several industries from fashion and automotive to construction and electronics. According to the Material Innovation Initiative, the alternative materials industry has seen an increased level of interest from investors who have dedicated over $2 billion into the sector since 2015.

“The time for rapid growth for biomaterials is now," says repeat investor Eric Rubenstein, founding managing partner at Houston-based New Climate Ventures, in the release. "BUCHA BIO's team and technical development are advancing hand in hand with the demands of brand partnerships, and we are excited to support them as they capitalize on this global opportunity.”

Eric Rubenstein of New Climate Ventures joins the Houston Innovators Podcast to discuss the future of Houston as a clean energy hub. Photo courtesy of NCV

Climate tech investor says Houston has a multifaceted role to play in the energy transition

houston innovators podcast episode 122

If the city of Houston wants to maintain its moniker of Energy Capital of the World, it has make strides within the energy transition — and that needs to be accomplished in a myriad of ways.

"Houston's role (within the energy transition) is multifaceted," says Eric Rubenstein, founding managing partner of New Climate Ventures, on this week's episode of the Houston Innovators Podcast.

Rubenstein founded New Climate Ventures to fund startups within the sustainability and climate tech space — which includes technologies that address circular economy, sustainably made materials, clean energy, and more.

"We have a talent pool here that fits pretty well in climate tech, alternative materials, and other spaces," he continues. "We have a customer base here that is going to adopt these new technologies."

The fact that Houston's major energy companies — of which there are many in town — will be the customers of emerging clean energy technologies positions the city as a hub for attracting innovative startups. Just last week, Bucha Bio, one of NCV's portfolio companies expanded into Houston. The New-York founded startup creates in textiles and composite materials made from bacterial nanocellulose, a much more sustainable materials production, that can be used instead of animal leather, polyurethane, latex, vinyl, epoxy, and more.

Rubenstein says Bucha Bio narrowed down its options to San Diego and Houston, before ultimately deciding on the Bayou City for its talent pool. The company, which is a member of Greentown Houston, is now based out of the East End Maker Hub.

"As these technologies are being spun out of labs, Houston has become a destination for these companies," Rubenstein says. "Bucha Bio isn't an irregular occurrence these days."

The missing piece of the puzzle is still venture dollars — and Rubenstein is on a mission to move that needle. This year, NCV is focused on closing its fund and deploying capital into early-staged climate tech companies.

"Our goal is really to watch for transformational change in the industries we're investing in," he says. "We're really excited about the technologies in the space and will continue looking for what's to come."

Rubenstein shares more about New Climate Ventures and the trend that is impact investing on the podcast. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Bucha Bio has arrived to make an impact on the city of Houston. Image courtesy of Bucha Bio

Sustainable biomaterials startup expands to Houston

new to hou

A New York-founded biomaterials company has announced the opening of operations in Houston after research found the region's workforce “perfectly suited to biomaterials.”

Bucha Bio, founded in 2019, creates in textiles and composite materials made from bacterial nanocellulose, a much more sustainable materials production, that can be used instead of animal leather, polyurethane, latex, vinyl, epoxy, and more. The company announced in a press release today that it's moving from New York City and opening a next-gen materials headquarters at the East End Maker Hub. Bucha Bio has also been accepted as a member company at Greentown Labs.

According to the release, over 20 locations were considered, and Houston stood out for its hiring potential, local universities, Texas's business-friendly regulation, and more.

“We’ve signed on senior scientists and their experiences from the oil and plastic industry are perfectly suited to biomaterials,” says Zimri T. Hinshaw, CEO of Bucha Bio, in the release.

One of these new local hires was Alex Kalin, who joined the company as senior materials scientist from Halliburton.

“It’s a great time to be involved in developing sustainable materials technologies," Kalin says in the release. "Having the opportunity to make a positive impact on the environment was a key factor for me joining Bucha Bio.”

Houston's chemical plant carbon footprint includes 56 gigatons tons of carbon that will be produced from now until 2050 — this number could be shrunk with sustainable alternatives like the one Bucha Bio provides. This potential has been recognized by Greentown Labs.

“Bringing world class energy transition companies like Bucha Bio to Houston is a win-win; not only is Bucha positioned to tap into a diverse talent pool from Universities such as Rice, University of Houston, and Texas A&M, but a wealth of extant talent which is looking to transition their careers; Zimri and his team bring more than technology to Houston, they bring the knowhow, vigor, and network it takes to build meaningful disruptive technology company," says Jason Ethier, senior director of memberships at Greentown Houston.

Last fall, Bucha Bio raised $550,000 in funding led by Houston-based New Climate Ventures with support from SOSV’s IndieBio.

“Bucha Bio’s move to Houston marks a milestone for their ability to keep up with the growing demand for their products and for our shared vision of a clean environment for generations to come," Eric Rubenstein of NCV says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston founder on shaping the future of medicine through biotechnology and resilience

Guest Column

Living with chronic disease has shaped my life in profound ways. My journey began in 5th grade when I was diagnosed with Scheuermann’s disease, a degenerative disc condition that kept me sidelined for an entire year. Later, I was diagnosed with hereditary neuropathy with liability to pressure palsies (HNPP), a condition that significantly impacts nerve recovery. These experiences didn’t just challenge me physically, they reshaped my perspective on healthcare — and ultimately set me on my path to entrepreneurship. What started as personal health struggles evolved into a mission to transform patient care through innovative biotechnology.

A defining part of living with these conditions was the diagnostic process. I underwent nerve tests that involved electrical shocks to my hands and arms — without anesthesia — to measure nerve activity. The pain was intense, and each test left me thinking: There has to be a better way. Even in those difficult moments, I found myself thinking about how to improve the tools and processes used in healthcare.

HNPP, in particular, has been a frustrating condition. For most people, sleeping on an arm might cause temporary numbness that disappears in an hour. For me, that same numbness can last six months. Even more debilitating is the loss of strength and fine motor skills. Living with this reality forced me to take an active role in understanding my health and seeking solutions, a mindset that would later shape my approach to leadership.

Growing up in Houston, I was surrounded by innovation. My grandfather, a pioneering urologist, was among the first to introduce kidney dialysis in the city in the 1950s. His dedication to advancing patient care initially inspired me to pursue medicine. Though my path eventually led me to healthcare administration and eventually biotech, his influence instilled in me a lifelong commitment to medicine and making a difference.

Houston’s thriving medical and entrepreneurial ecosystems played a critical role in my journey. The city’s culture of innovation and collaboration provided opportunities to explore solutions to unmet medical needs. When I transitioned from healthcare administration to founding biotech companies, I drew on the same resilience I had developed while managing my own health challenges.

My experience with chronic disease also shaped my leadership philosophy. Rather than accepting diagnoses passively, I took a proactive approach questioning assumptions, collaborating with experts, and seeking new solutions. These same principles now guide decision-making at FibroBiologics, where we are committed to developing groundbreaking therapies that go beyond symptom management to address the root causes of disease.

The resilience I built through my health struggles has been invaluable in navigating business challenges. While my early career in healthcare administration provided industry insights, launching and leading companies required the same determination I had relied on in my personal health journey.

I believe the future of healthcare lies in curative treatments, not just symptom management. Fibroblast cells hold the promise of engaging the body’s own healing processes — the most powerful cure for chronic diseases. Cell therapy represents both a scientific breakthrough and a significant business opportunity, one that has the potential to improve patient outcomes while reducing long-term healthcare costs.

Innovation in medicine isn’t just about technology; it’s about reimagining what’s possible. The future of healthcare is being written today. At FibroBiologics, our mission is driven by more than just financial success. We are focused on making a meaningful impact on patients’ lives, and this purpose-driven approach helps attract talent, engage stakeholders, and differentiate in the marketplace. Aligning business goals with patient needs isn’t just the right thing to do, it’s a powerful model for sustainable growth and lasting innovation in biotech.

---

Pete O’Heeron is the CEO and founder of FibroBiologics, a Houston-based regenerative medicine company.


Houston researchers make headway on affordable, sustainable sodium-ion battery

Energy Solutions

A new study by researchers from Rice University’s Department of Materials Science and NanoEngineering, Baylor University and the Indian Institute of Science Education and Research Thiruvananthapuram has introduced a solution that could help develop more affordable and sustainable sodium-ion batteries.

The findings were recently published in the journal Advanced Functional Materials.

The team worked with tiny cone- and disc-shaped carbon materials from oil and gas industry byproducts with a pure graphitic structure. The forms allow for more efficient energy storage with larger sodium and potassium ions, which is a challenge for anodes in battery research. Sodium and potassium are more widely available and cheaper than lithium.

“For years, we’ve known that sodium and potassium are attractive alternatives to lithium,” Pulickel Ajayan, the Benjamin M. and Mary Greenwood Anderson Professor of Engineering at Rice, said in a news release. “But the challenge has always been finding carbon-based anode materials that can store these larger ions efficiently.”

Lithium-ion batteries traditionally rely on graphite as an anode material. However, traditional graphite structures cannot efficiently store sodium or potassium energy, since the atoms are too big and interactions become too complex to slide in and out of graphite’s layers. The cone and disc structures “offer curvature and spacing that welcome sodium and potassium ions without the need for chemical doping (the process of intentionally adding small amounts of specific atoms or molecules to change its properties) or other artificial modifications,” according to the study.

“This is one of the first clear demonstrations of sodium-ion intercalation in pure graphitic materials with such stability,” Atin Pramanik, first author of the study and a postdoctoral associate in Ajayan’s lab, said in the release. “It challenges the belief that pure graphite can’t work with sodium.”

In lab tests, the carbon cones and discs stored about 230 milliamp-hours of charge per gram (mAh/g) by using sodium ions. They still held 151 mAh/g even after 2,000 fast charging cycles. They also worked with potassium-ion batteries.

“We believe this discovery opens up a new design space for battery anodes,” Ajayan added in the release. “Instead of changing the chemistry, we’re changing the shape, and that’s proving to be just as interesting.”

---

This story originally appeared on EnergyCapitalHTX.com.

FAA demands investigation into SpaceX's out-of-control Starship flight

Out of this world

The Federal Aviation Administration is demanding an accident investigation into the out-of-control Starship flight by SpaceX on May 27.

Tuesday's test flight from Texas lasted longer than the previous two failed demos of the world's biggest and most powerful rocket, which ended in flames over the Atlantic. The latest spacecraft made it halfway around the world to the Indian Ocean, but not before going into a spin and breaking apart.

The FAA said Friday that no injuries or public damage were reported.

The first-stage booster — recycled from an earlier flight — also burst apart while descending over the Gulf of Mexico. But that was the result of deliberately extreme testing approved by the FAA in advance.

All wreckage from both sections of the 403-foot (123-meter) rocket came down within the designated hazard zones, according to the FAA.

The FAA will oversee SpaceX's investigation, which is required before another Starship can launch.

CEO Elon Musk said he wants to pick up the pace of Starship test flights, with the ultimate goal of launching them to Mars. NASA needs Starship as the means of landing astronauts on the moon in the next few years.

View All Listings